Press release Communiqué de presse
Press release Communiqué de presse
April 7, 2010 7 April, 2010
Sernova To Present At Biofinance Canada Conference
Source: Sernova Corp.
Wednesday, April 7, 2010, 6:00 a.m. EDT
LONDON, ONTARIO--(Marketwire - April 7, 2010) - Sernova Corp. (TSX-V:SVA), a company focused on product development and commercialization of innovative medical technologies for cell therapies, announced that its President & Chief Executive Officer will present an overview of the company's technology to a select group of biotech industry investors at the BioFinance Conference in Toronto, Ontario, Canada. Sernova's presentation is scheduled for 4:00 p.m. April 7, 2010.
The proprietary Cell Pouch System(TM), Sernova's lead technology is a novel, matchbook size medical device that is placed under the skin in a simple procedure. Once implanted, the device becomes a vascularised organ-like structure and provides the microcirculation essential to early function and long-term survival of transplanted therapeutic cells. Sernova believes the Cell Pouch System(TM) offers a valuable potential improvement to the current practise of injecting therapeutic cells directly into the bloodstream. Sernova's first application is in support of islet transplantation for treatment of insulin- dependent diabetes, where the Cell Pouch System(TM) is expected to prevent the instant blood-mediated inflammatory reaction (IBMIR) believed to rapidly destroy up to an estimated 90% of the transplanted islets and in addition eliminate serious complications such as islet- induced blood clotting and liver thrombosis. The reduction in islet loss, once verified, could lead to improved safety and efficacy of islet transplantation and the potential of treating multiple patients from a single pancreas donation.
About Sernova Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.
For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 firstname.lastname@example.org www.sernova.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.